Quantitative Fluorescence Endoscopy Using Durvalumab-680LT in Esophageal Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Treatment of patients with locally advanced esophageal cancer (EC) is multidisciplinary and
consists of neoadjuvant therapy followed by surgical removal of the esophageal tumor and
potentially tumor positive lymph nodes. The beneficial effect of the addition of
immunotherapy to improve response rates to current treatment strategies has been investigated
response to, since only 16 to 43% of EC patients achieve a pathological complete response
(pCR) after neoadjuvant therapy and a pCR is associated with better long-term outcomes.
Unfortunately, not all patients respond to immunotherapy and the knowledge about biomarkers
that predict response to therapy are required. A promising novel parameter is tumor
programmed death-ligand 1 (PD-L1) expression, one of the immune checkpoints targeted by
cancer immunotherapy. Studies performed in patients with various solid tumors demonstrate
improved response to immunotherapy and survival benefit in patients with higher PD-L1
expression. Nonetheless, not all patients with high PD-L1 expression show benefit and some
without expression do. Moreover, mostly biopsy-based tests are used to assess PD-L1 status,
although these tests are prone to errors, partly due to heterogeneity in tissue expression.
Novel methods are needed to gain more insight in the PD-L1 expression in order to better
select patients who are likely to benefit from immunotherapy. The investigators hypothesize
that quantitative fluorescence endoscopy using the tracer durvalumab-680LT targeting PD-L1 is
a promising technique to investigate the heterogeneity of PD-L1 expression.
Phase:
Phase 1
Details
Lead Sponsor:
University Medical Center Groningen
Collaborator:
Cambridge University Hospitals NHS Foundation Trust